Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-5670a booster versus approved mRNA COVID-19 vaccine boosters in Japanese adults and elderly
jRCT2071210106Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, single-blind trial of DS-5670a in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Geometric mean fold rise of neutralizing antibody titer, Specific adverse events and adverse reactions and 4 more. Started Jan 2022; status: completed.
02
Drugs
DS-5670a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071210106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210106.